Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mokobio Life Science Corporation Beijing manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. There is currently 1 pending office action associated with this portfolio. The prosecution involves 1 distinct examiner and 1 distinct art unit for all active matters. This focus within the Biotechnology & Pharmaceuticals sector suggests that the company's current patenting efforts are directed toward a specific technological application. Practitioners can expect a streamlined interaction with the patent office due to the 1 pending office action.
PARISI, JESSICA DANIELLE serves as the busiest examiner, with 1 busiest examiner pending office action. Because the total pending office actions for the Biotechnology & Pharmaceuticals filings also equals 1, this examiner is the sole official currently reviewing the company's pending applications. This concentration simplifies the tracking of prosecution trends for the portfolio. However, it also means that the company's success is dependent on the examiner's interpretation of the claims within that 1 distinct art unit. Strategy should be tailored to the specific requirements of PARISI, JESSICA DANIELLE.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARISI, JESSICA DANIELLE | 1 | 75.0% | +33.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270492 | METHOD FOR CONSTRUCTING MULTIPLEX PCR LIBRARY FOR HIGH-THROUGHPUT TARGETED SEQUENCING | PARISI, JESSICA DANIELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18270492 | METHOD FOR CONSTRUCTING MULTIPLEX PCR LIBRARY FOR HIGH-THROUGHPUT TARGETED SEQUENCING | PARISI, JESSICA DANIELLE | — |
| Art Unit | Apps |
|---|---|
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18270492 | METHOD FOR CONSTRUCTING MULTIPLEX PCR LIBRARY FOR HIGH-THROUGHPUT TARGETED SEQUENCING | PARISI, JESSICA DANIELLE | 1684 | §102§112 | Non-Final OA | — | Pending | Jun 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMokobio Life Science Corporation Beijing has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jessica Danielle Parisi has the most, with 1 of Mokobio Life Science Corporation Beijing's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
